Nexium news from FiercePharma
NewsAZ reaffirms whole-hog API outsourcing
Remember last fall when AstraZeneca EVP David Smith said the company was looking to outsource most of its Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring Read more...
AstraZeneca, Ranbaxy settle Nexium fight
AstraZeneca investors were jumping for joy this morning when the drugmaker announced it had played Let's Make a Deal with Indian generics maker Ranbaxy. The copycat company agreed to wait till 2014 Read more...
AstraZeneca rivals could launch any day
You can bet the execs at AstraZeneca are biting their nails this week. Next Monday, April 14, marks the end of a 30-month stay on Ranbaxy Laboratories' copycat form of the mega-blockbuster Nexium. Read more...
| Press ReleasesPRESS RELEASE: FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events Background: On May 29, 2007 AstraZeneca, the maker of Prilosec (omeprazole) and Nexium Read more... |
Get more Nexium coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends